Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway

Journal of the American College of Cardiology

Volumn 43, Issue 8, 2004, Pages 1481-1488

  Ogata, Takehiro ^a   Miyauchi, Takashi ^a   Sakai, Satoshi ^a   Takanashi, Masakatsu ^a   Irukayama Tomobe, Yoko ^a   Yamaguchi, Iwao ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

dP dt max; COX 2; Cyclooxygenase 2; Deoxycorticosterone acetate; Deoxycorticosterone acetate salt rats treated with fenofibrate; Deoxycorticosterone acetate salt rats treated with vehicle; DOCA; DOCA F; DOCA V

Indexed keywords

CYCLOOXYGENASE 2; DEOXYCORTICOSTERONE ACETATE; FENOFIBRATE; HYDROXYPROLINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROCOLLAGEN; SODIUM CHLORIDE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE FIBROSIS; HYPERTENSION; INFLAMMATION; INTERMETHOD COMPARISON; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RANDOMIZATION; RAT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; UPREGULATION;

ANIMALS; ANTILIPEMIC AGENTS; BLOTTING, WESTERN; CARDIAC OUTPUT, LOW; DESOXYCORTICOSTERONE; DIASTOLE; FIBROSIS; GENE EXPRESSION; HEMODYNAMIC PROCESSES; HYPERTENSION; I-KAPPA B PROTEINS; MALE; MYOCARDIUM; NF-KAPPA B; PROCETOFEN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM CHLORIDE; TRANSCRIPTION FACTORS;

EID: 1942484870     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.11.043     Document Type: Article

References (33)

1. Vasan R.S., Larson M.G., Benjamin E.J., et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol. 33:1999;1948-1955.
2. Staels B., Koenig W., Habib A., et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR-alpha but not by PPAR-gamma activators. Nature. 393:1998;790-793.
3. 4 pathway to inflammation control. Nature. 384:1996;39-43.
4. Watanabe K., Fujii H., Takahashi T., et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferators-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem. 275:2000;22293-22299.
5. Ross R. The pathogenesis of atherosclerosis A perspective for the 1990s. Nature. 362:1993;801-809.
6. Saitoh K., Mori T., Kasai H., et al. Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits. Nippon Yakurigaku Zasshi. 106:1995;41-50.
7. Ericsson C.G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfaction patients. Lancet. 347:1996;849-853.
8. Delerive P., Bosscher K., Besnard S., et al. Peroxisome proliferators-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factor NF-kappa-B and AP-1. J Biol Chem. 274:1999;32048-32054.
9. Poynter M.E., Daynes R.A. Peroxisome proliferators-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappa-B signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 273:1998;32833-32841.
10. Ogata T., Miyauchi T., Sakai S., et al. Stimulation of peroxisome proliferators-activated receptor alpha (PPAR-alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci. 103 Suppl:2002;284S-288S.
11. a receptor antagonism. Circulation. 103:2001;319-324.
12. Matsumura Y., Kuro T., Kobayashi Y., et al. Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation. 102:2000;2765-2773.
13. Nagayama T., Tsuchiya A., Arakawa L., et al. Hypolipidemic action of fenofibrate and bezafibrate in normo- and hyperlipidemic animals. Jpn Pharmacol Ther. 23:(Suppl 4):1995;181-188.
14. Yamamoto K., Nishimura R.A., Chaliki H.P., et al. Determination of left ventricular filling pressure by Doppler echocardiography in patients with coronary artery disease Critical role of left ventricular systolic function. J Am Coll Cardiol. 30:1997;1819-1826.
15. Yamamoto K., Masuyama T., Sakata Y., et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res. 55:2002;76-82.
16. Miyauchi T., Yorikane R., Sakai S., et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alteration in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 73:1993;887-897.
17. Sakai S., Miyauchi T., Kobayashi M., et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384:1996;353-355.
18. Sakai S., Miyauchi T., Sakurai T., et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure Marked increase in endothelin-1 production in the failing heart. Circulation. 93:1996;1214-1222.
19. Stegemann H., Stalder K. Determination of hydroxyproline. Clin Chim Acta. 18:1967;267-273.
20. Yamauchi-Kohno R., Miyauchi T., Hoshino T., et al. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters Increase in endothelin-1 production in the heart and beneficial effect of endothelin a antagonist on survival and cardiac function. Circulation. 99:1999;2171-2176.
21. Shen Z., Peedikayil J., Olson G.K., et al. Multiple transcription factors profiling by enzyme-linked immunoassay. Biotechniques. 32:2002;1168,70-1168,72. ,74.
22. Pessara U., Koch N. Tumor necrosis factor-alpha regulates expression of the major histocompatibility complex class II-associated invariant chain by binding of an NF-kappa-B-like factor to a promoter element. Mol Cell Biol. 10:1990;4146-4154.
23. Burlew B.S., Weber K.T. Cardiac fibrosis as a cause of diastolic dysfunction. Herz. 27:2002;92-98.
24. Sugihara N., Genda A., Shimizu M., et al. Diastolic dysfunction and its relation to myocardial fibrosis in essential hypertension. J Cardiol. 18:1988;353-361.
25. Brilla C.G., Janicki J.S., Weber K.T. Impaired diastolic function and coronary reserve in genetic hypertension Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res. 69:1991;107-115.
26. Iglarz M., Touyz R.M., Viel E.C., et al. Peroxisome proliferators- activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension. 42:2003;737-743.
27. Nicoletti A., Michel J.B. Cardiac fibrosis and inflammation Interaction with hemodynamic and hormonal factors. Cardiovasc Res. 41:1999;532-543.
28. Border W.A., Noble N.A. Transforming growth factor-beta in tissue fibrosis. N Engl J Med. 331:1994;1286-1292.
29. Hinglais N., Heudes D., Nicoletti A., et al. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest. 70:1994;286-294.
30. Shahar I., Fireman E., Topilsky M., et al. Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung disease. Clin Immunol Immunopathol. 79:1996;244-251.
31. Altavilla D., Deodato B., Campo G., et al. IRFI042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kappa-B and reduces the inflammatory response in myocardial ischemia-reperfusion injury. Cardiovasc Res. 47:2000;515-528.
32. Delerive P., Gervois P., Fruchart J.C., et al. Induction of I-kappa-B-alpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferators-activated receptor-alpha activators. J Biol Chem. 275:2000;36703-36707.
33. Marx N., Sukhova G.K., Collins T., et al. PPAR-alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 99:1999;3125-3131.